November 5, 2018Open Access

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

relapse following CD19-directed CAR therapy. The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce risk of antigen loss.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Qin et al. (Mon,) studied this question.

synapsesocial.com/papers/6a0870ed7de338f10b10afff https://doi.org/https://doi.org/10.1016/j.omto.2018.10.006

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia2012 · 584 citations
2Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases2011 · 223 citations
3Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models2017 · 6 citations
4TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy2013 · 459 citations
5CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy2017 · 1,349 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo